Inavolisib (GDC-0077) is a potent, orally active, and selective PI3Kalpha inhibitor (IC50=0.038 nM). Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Inavolisib is more selective for mutant versus wild-type PI3Kalpha. Inavolisib can be used for the study of breast cancer[1].
Molecular Weight:
407.37
Purity:
99.96
CAS Number:
[2060571-02-8]
Formula:
C18H19F2N5O4
Target:
Apoptosis,PI3K
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
